HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

DESTINY-Breast04: T-DXd for patients with HER2-low mBCПодробнее

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expressionПодробнее

Efficacy of trastuzumab deruxtecan in HER2-low metastatic breast cancerПодробнее

Clinical outcomes in women with metastatic HER2-low breast cancer in the real worldПодробнее

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJMПодробнее

Trastuzumab deruxtecan shows benefit in patients with HER2 + mBCПодробнее

Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBCПодробнее

Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer | Dr. Jitendra PahlajaniПодробнее

The exciting new field of HER2-low breast cancerПодробнее

HER2-low expression in breast cancerПодробнее

Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast CancerПодробнее

The significance of HER2 expression for the activity of trastuzumab deruxtecanПодробнее

DESTINY-Breast04: practice-changing results for HER2-low breast cancerПодробнее

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer ptsПодробнее

Is HER2-low a distinct subtype of breast cancer?Подробнее

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patientsПодробнее

Trastuzumab deruxtecan: a promising agent for treating HER2-low breast cancer?Подробнее

New treatment for HER2 low metastatic breast cancer (HB 422)Подробнее

ASCO 2022: Trastuzumab deruxtecan vs. treatment of physician's choice in HER2-low unresectable a...Подробнее